In an effort to identify novel drugs targeting fusion-oncogene–induced acute myeloid leukemia
(AML), we performed high-resolution proteomic analysis. In AML1-ETO (AE)-driven AML, …

Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by recurrent
mutations in genes encoding transcriptional, chromatin, and/or signaling regulators. The t(8;21) …

During somatic reprogramming, Yamanaka's pioneer factors regulate a complex sequence
of molecular events leading to the activation of a network of pluripotency factors, ultimately …

This protocol offers a detailed procedure for the in vitro differentiation of human pluripotent
stem cells (hPSCs) to multipotent hematopoietic progenitors that arise from SOX17 + …

Acute myeloid leukemia is a hematopoietic malignancy caused by recurrent mutations in
genes encoding transcriptional, epigenetic and/or signaling regulators. The t(8;21) …

Acute Myeloid Leukaemia results from the successive acquisition of multiple genetic
aberrations. Therefore, the sole study of patient samples, which represent the end-point of this …

E-mail: CONSTANZE BONIFER-c. bonifer@ bham. ac. uk doi: 10.3324/haematol. 2019.230029
occur in genes encoding for the growth factor receptors KIT and FLT3, 20, 21 rendering …

The t(8;21) translocation generates the aberrant transcription factor RUNX1-ETO and occurs
in approximately 10% of all acute myeloid leukaemias. RUNX1-ETO transcripts can be …

Chromosomal translocations found in acute myeloid leukemia (AML) can generate oncogenic
fusions with aberrant epigenetic and transcriptional functions. However, direct therapeutic …

Background Respiratory failure is a key feature of severe Covid-19 and a critical driver of
mortality, but for reasons poorly defined affects less than 10% of SARS-CoV-2 infected patients. …